GENE ONLINE|News &
Ascendis Pharma to Consolidate Listings by Moving Ordinary Shares to Nasdaq
Ascendis Pharma announced plans to list its ordinary shares directly on the Nasdaq Stock Market. The company, which specializes in developing therapies for rare endocrine diseases, confirmed this move as part of its ongoing efforts to expand access to its stock for investors and streamline its trading process.
The decision marks a shift from Ascendis Pharma’s previous dual listing structure, where its American Depositary Shares (ADS) were traded on Nasdaq while ordinary shares were listed on the Copenhagen Stock Exchange. By consolidating its listings onto Nasdaq, the company aims to simplify trading and align with international investor preferences. Ascendis Pharma stated that this transition would not impact shareholders holding ADS or ordinary shares, and further details regarding the timeline and procedural changes will be provided in due course.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 8, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Fire Incident Reported at Crushing Circuit of B2Gold’s Goose Mine Project on April 18, 2026
2026-04-18
Study in BMC Geriatrics Examines Differing Views of Healthcare Professionals and Families on Deprescribing Preventive Medications for Dementia Patients
2026-04-18
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
